Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)

Abstract

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in combination with fludarabine and/or cyclophosphamide, or ALLO-647 alone. Phase: PHASE1 Status: COMPLETED Conditions: Relapsed/Refractory Multiple Myeloma Interventions: ALLO-715; ALLO-647; Fludarabine; Cyclophosphamide; Nirogacestat

Keywords

Sources